



## Press Release

### **Qualitix Clinical Research Co., Ltd. and ACTS Biosciences, Inc. entered a strategic partnership agreement**

Taipei, Taiwan (November 10, 2009) –Taiwan’s fast-growing CRO Qualitix Clinical Research Co., Ltd. and ACTS Biosciences, Inc. solely devoted to personalized medicine development announced that the two companies have entered a strategic partnership agreement to provide comprehensive clinical research services in the Asia-Pacific region. This alliance will allow the companies to offer integrated services of pharmacogenomics and traditional CRO under one umbrella to Pharmaceutical clients.

Dr. Stephen T. Chen, Chairman and Chief Executive Officer, ACTS Biosciences, Inc. stated “Our collaboration will offer cost-effective and efficient CRO services to the clients that can accelerate their drug development program”. ACTS sister companies (Vita Genomics, Inc. and Shanghai GeneCore Biotechnologies, Co., Ltd.) located in Taiwan and China are equipped with the most advanced platform technologies, ISO accredited laboratories, and highly qualified scientific team to aid drug development process at different stages of clinical trials through genomics/ pharmacogenomics approaches. ACTS has established collaborations with top International pharmaceutical and Biotechnology companies.

Dr. Jen Chen, Chairman of Qualitix Clinical Research Co., Ltd stated “This strategic partnership would enhance our clinical research services and enable us to offer high quality pharmacogenomics services in addition to our regular clinical trial services to our existing and potential future clients”. Qualitix is embracing a business model of “Being a Total Solution CRO in Medical Development”, and believes value added services are important elements for strengthening company capacity and competitiveness. Qualitix, over the past few years has established partnerships with CROs around the globe including Novotech (Australia), Asklep (Japan), Dream CIS (Korea), ASKA Research (North America), Harrison Clinical Research Group (Europe), and MakroCare (India).

Both the companies would aim to jointly market their services and explore new business opportunities with specific emphasis in oncology related therapies.

#### **About Qualitix Clinical Research Co., Ltd.**

With abundant experience and know-how, Qualitix ([www.qualitix.com.tw](http://www.qualitix.com.tw)) helps pharmaceutical, biotech and device manufacturers plan and manage trials from beginning to end. Qualitix strengths are study consulting and study design, medical writing and feasibility for patient recruitment along with subsequent clinical monitoring, data Management, and Biometrics. Qualitix provides clinical trial services either for an entire project or certain stages of a project that meet client needs, in accordance with Taiwan GCP, ICH GCP and ICH guidelines. Since 2004, Qualitix has conducted 155 clinical trials in Phase I to IV and Post-Marketing Surveillance.

## **About ACTS Biosciences, Inc.**

ACTS Biosciences, Inc. ([www.actsbiosciences.com](http://www.actsbiosciences.com)) is an exclusive marketing partner and a member of VitaBiotech group. Two members of the group, Vita Genomics, Inc. ([www.vitagénomics.com](http://www.vitagénomics.com)) and Shanghai GeneCore BioTechnologies Co., Ltd. ([www.genecore.com/old/english](http://www.genecore.com/old/english)) provide comprehensive and high quality Genomics and Pharmacogenomics services in Taiwan and China, respectively. ACTS focuses on marketing and distribution of innovative products and services to the pharmaceutical and healthcare industries with specific emphasis on unmet medical needs. ACTS has integrated the science of pharmacogenomics, the technology of drug delivery systems and innovative business execution strategies to improve and expedite the drug development process. ACTS aims to play key role in the development and introduction of personalized medicines, and eventually lower overall healthcare costs. ACTS has established its offices in USA, China and Taiwan to serve the needs of various clients around the globe.

Contact person and address:

Mr. Min-hsiung Kao  
General Manager  
Qualitix Clinical Research Co., Ltd.  
Tel: +886-2-3393-1388#188  
Fax: +886-2-2351-0607  
Email: [mhkao@qualitix.com.tw](mailto:mhkao@qualitix.com.tw)  
5F, No.12, Ren-Ai Road, Section 2, Taipei 10060, Taiwan